Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple myeloma
| Condition | Intervention | Phase |
|---|---|---|
|
Refractory Multiple Myeloma Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma |
Drug: alvocidib |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Study of Flavopiridol in Patients With Relapsed and Refractory Multiple Myeloma |
- Confirmed response (CR, VGPR, or PR) defined as a patient who has achieved response and maintained it on two consecutive evaluations at least 4 weeks apart. [ Time Frame: First 3 months of treatment ] [ Designated as safety issue: No ]Ninety percent confidence intervals for the true success proportion will be calculated assuming a binomial distribution.
- Overall survival time [ Time Frame: Time from registration to death due to any cause, assessed up to 1 year ] [ Designated as safety issue: No ]The distribution of survival time will be estimated using the method of Kaplan-Meier.
- Time to disease progression [ Time Frame: Time from registration to documentation of disease progression, assessed up to 1 year ] [ Designated as safety issue: No ]The distribution of time to progression will be estimated using the method of Kaplan-Meier.
| Enrollment: | 35 |
| Study Start Date: | September 2002 |
| Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment (flavopiridol)
Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
|
Drug: alvocidib
Given IV
Other Names:
|
Detailed Description:
PRIMARY OBJECTIVES:
I. Determine the response rate in patients with relapsed or refractory multiple myeloma treated with flavopiridol.
II. Determine the disease-free survival and overall survival of patients treated with this drug.
III. Correlate disease response with t(11;14)(q13;q32) rearrangement, p16 methylation status, and BCRP expression in patients treated with this drug.
IV. Correlate disease response and drug treatment with cell cycle status and effects on apoptosis and apoptosis regulatory proteins in these patients.
OUTLINE: This is a multicenter study.
Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 1 year.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of relapsed or refractory multiple myeloma (MM) requiring treatment
Durie-Salmon stage I or greater at diagnosis
- Patients with non-secretory or oligo-secretory MM (defined as maximum urinary M-spike less than 200 mg/24 hours and a maximum serum M-spike less than 0.5 g/dL during entire disease course) must have at least 30% bone marrow plasma cells
- Patients with secretory MM must have measurable disease defined as serum monoclonal protein of at least 1 g/dL or urinary M-spike of at least 200 mg/24 hours
Must have received at least 1, but no more than 5 prior therapy regimens
- Patients who have had 4 or 5 regimens are allowed provided corticosteroids and/or thalidomide are part of the regimens
- No more than 5 prior chemotherapy regimens (as long as 2 contained dexamethasone or thalidomide)
- Prior autologous peripheral blood stem cell transplantation is considered 1 prior regimen
- Performance status - ECOG 0-2
- Performance status - ECOG 0-3 if secondary to neuropathy or acute bone event (e.g., vertebral compression or rib fracture)
- Absolute neutrophil count at least 750/mm^3
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 2.5 times ULN
- AST no greater than 2.5 times ULN
- Creatinine no greater than 3 mg/dL
- No myocardial infarction within the past 6 months
- Peripheral neuropathy secondary to prior drug therapy or myeloma-associated neuropathy allowed
- No other uncontrolled serious medical condition
- No uncontrolled infection
- No other active malignancy
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- See Disease Characteristics
- No prior allogeneic stem cell transplantation
- At least 10 days since prior thalidomide
- No concurrent biologic therapy
- See Disease Characteristics
- At least 2 weeks since prior myelosuppressive chemotherapy
- No other concurrent chemotherapy
- See Disease Characteristics
No concurrent corticosteroids (including as antiemetics) except chronic corticosteroids for disorders other than myeloma (e.g., rheumatoid arthritis or adrenal insufficiency)
- Maximum dose allowed for prednisone is no more than 10 mg/day or hydrocortisone no more than 40 mg/day
- At least 10 days since prior bortezomib or tipifarnib
- Concurrent bisphosphonates allowed if on stable dose before study entry
Contacts and Locations More Information
No publications provided
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00047203 History of Changes |
| Other Study ID Numbers: | NCI-2012-02496, MC018B, N01CM17104, CDR0000257567 |
| Study First Received: | October 3, 2002 |
| Last Updated: | January 15, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders |
Immunoproliferative Disorders Immune System Diseases Flavopiridol Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Growth Inhibitors Growth Substances Physiological Effects of Drugs Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 18, 2013